Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections-Reference-Cited by-同舟云学术

Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections

Published:2023 Issue:4 Volume:25 Page:366-371
ISSN:2686-9586
Container-title:Clinical Microbiology and Antimicrobial Chemotherapy
language:ru
Short-container-title:CMAC

Author:

Avdeev Sergey N.¹^ORCID,Andreeva Irina V.²^ORCID,Gorelov A.V.¹,Gurov A.V.³,Dekhnich Andrey V.²^ORCID,Zyryanov Sergey K.⁴^ORCID,Karpova E.P.⁵,Kozlov Roman S.⁶^ORCID,Leshchenko I.V.⁷,Ovchinnikov A.Yu.⁸,Rachina Svetlana A.¹,Ryazantsev S.V.⁹,Svistushkin V.M.¹,Sinopalnikov Alexander I.⁵^ORCID,Stetsiouk Olga U.²^ORCID

Affiliation:

1. First Moscow State Medical University named after. I.M. Sechenov (Moscow, Russia)

2. Institute of Antimicrobial Chemotherapy (Smolensk, Russia)

3. Russian National Research Medical University named after. N.I. Pirogov (Moscow, Russia)

4. Russian Peoples' Friendship University; City Clinical Hospital No. 24" of the Moscow Department of Health (Moscow, Russia)

5. Russian Medical Academy of Continuing Professional Education (Moscow,Russia)

6. Institute of Antimicrobial Chemotherapy; Smolensk State Medical University (Smolensk, Russia)

7. Ural State Medical University

8. Moscow State Medical and Dental University named after. A.I. Evdokimov (Moscow,Russia)

9. North-Western State Medical University named after. I.I. Mechnikov; St. Petersburg Research Institute of Ear, Throat, Nose and Speech (St. Petersburg, Russia)

Abstract

The purpose of the expert council was to determine the place of cefpodoxime in the ABT algorithms for upper and lower respiratory tract infections and to form a consensus position on its use in clinical practice. Based on the available data, the possibility of including cefpodoxime in national guidelines for the treatment of rhinosinusitis, acute tonsillopharyngitis, community-acquired pneumonia (CAP), as well as infectious exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) is being considered.

Publisher

Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy

Reference36 articles.

1. The Lancet. Antimicrobial resistance: time to repurpose the Global Fund. Lancet. 2022;399(10322):335. DOI: 10.1016/S0140-6736(22)00091-5

2. Ivanchik N.V., Chagaryan А.N., Sukhorukova М.V., Kozlov R.S., Dekhnich А.V., Krechikova О.I., et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study «PEHASus 2014-2017». Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(3):230-237. Russian. DOI: 10.36488/cmac.2019.3.230-237

3. On the use of antibacterial therapy in patients with a new coronavirus infection COVID-19. Terpevticheskij arhiv. 2020;11:4. Russian.

4. Kuzmenkov A.Yu., Vinogradova A.G., Trushin I.V., Edelstein M.V., Avramenko A.A., Dekhnich A.V., Kozlov R.S. AMRmap – antibiotic resistance surveillance system in Russia. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2017;19(2):84-90. Russian. DOI: 10.36488/cmac.2021.2.198-204

5. Vanderkooi O.G., Low D.E., Green K., Powis J.E., McGeer A.; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial assistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40(9):1288-1297. DOI: 10.1086/429242